12月24日，Enanta Pharmaceuticals周二表示，将对美国联邦法院支持辉瑞)在与新冠抗病毒药物Paxlovid相关的专利侵权案中的裁决提出上诉。
据了解，两者的专利之争始于2022年，当时Enanta在马萨诸塞州地方法院起诉辉瑞，要求赔偿其在制造、使用和销售Paxlovid过程中涉嫌侵犯其美国专利号11358953的损失。
该公司表示，在对辉瑞提出的即决判决动议的裁决中，法院裁定其11358953专利无效。Enanta补充道，它将向美国上诉法院提起上诉。
首席执行官Jay Luly表示：“我们对法院的裁决感到失望。我们坚信我们案件的是非曲直，通过上诉程序，我们将继续为我们的发明辩护，防止非法侵权。”
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.